BDTX revenueQ2 2026$0
BDTX revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $70.00M, compared with $0 in fiscal 2024. Fiscal 2025 is the highest of the 5 fiscal years on file.
Black Diamond Therapeutics Inc. (BDTX) financials
For the twelve months ended Jun 30, 2026, Black Diamond Therapeutics Inc. reported $0 of revenue and -$42.55M of net income.
- Revenue, TTM
- $0
- Revenue growth, YoY
- -100.0%
- Net income, TTM
- -$42.55M
- EPS, diluted, TTM
- -$0.73
- Cash
- $19.19M
- Market cap
- $106.6M
FY2018FY2025
FY2018FY2025
FY2018FY2024
BDTX revenue and earnings growth
BDTX net incomeQ2 2026-$9.90M
BDTX net income was -$9.90M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$10.56M a year earlier. For the full fiscal 2025 it was $22.37M, compared with -$69.68M in fiscal 2024. Fiscal 2025 is the highest of the 8 fiscal years on file.
BDTX EPSQ2 2026-$0.17
BDTX diluted EPS was -$0.17 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.19 a year earlier. For the full fiscal 2025 it was $0.39, compared with -$1.27 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.00M | $0 | - | - | - | $0 | $0 | $0 |
| Research and development | $33.56M | $51.31M | $59.35M | $64.44M | $96.83M | $48.21M | $21.75M | $6.95M |
| Selling, general and admin | $16.57M | $27.47M | $27.11M | $28.39M | $30.04M | $21.36M | $7.58M | $1.95M |
| Operating income | $12.52M | -$78.78M | -$86.46M | -$92.83M | -$126.87M | -$69.57M | -$29.33M | -$8.90M |
| Interest expense | - | - | - | - | $0 | $1.0K | $0 | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $22.37M | -$69.68M | -$82.44M | -$91.17M | -$125.60M | -$67.25M | -$35.26M | -$8.93M |
| EPS, basic | $0.39 | -$1.27 | -$1.88 | -$2.52 | -$3.47 | -$2.05 | -$16.99 | -$4.42 |
| EPS, diluted | $0.39 | -$1.27 | -$1.88 | -$2.52 | -$3.47 | -$2.05 | -$16.99 | -$4.42 |
| Diluted shares | 57.6M | 55.0M | 44.0M | 36.3M | 36.2M | 32.9M | 2.1M | 2.0M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.99M | $37.26M | $57.04M | $35.48M | $67.02M | $35.83M | $154.72M | $51.66M |
| Current assets | $132.44M | $101.18M | $134.03M | $127.71M | $215.70M | $319.55M | $155.71M | $51.68M |
| Total assets | $143.01M | $122.64M | $158.57M | $156.25M | $247.68M | $329.67M | $158.29M | $51.83M |
| Current liabilities | $15.73M | $20.57M | $19.65M | $15.26M | $23.64M | $14.22M | $4.86M | $2.58M |
| Total liabilities | $30.80M | $39.35M | $41.83M | $40.56M | $51.78M | $21.91M | $4.88M | $6.60M |
| Shareholders' equity | $112.21M | $83.28M | $116.74M | $115.69M | $195.90M | $307.76M | -$47.16M | -$15.54M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $29.61M | -$62.30M | -$66.72M | -$85.08M | -$100.15M | -$52.15M | -$24.67M | -$8.45M |
| Capital expenditures | - | $0 | $33.0K | $192.0K | $2.71M | $142.0K | $21.0K | $76.0K |
| Free cash flow | - | -$62.30M | -$66.75M | -$85.27M | -$102.86M | -$52.29M | -$24.70M | -$8.53M |
| Investing cash flow | -$44.91M | $16.97M | $16.35M | $53.37M | $130.61M | -$281.69M | -$21.0K | -$76.0K |
| Financing cash flow | -$146.0K | $25.55M | $71.93M | $177.0K | $729.0K | $214.94M | $127.76M | $52.31M |
| Stock-based compensation | $6.63M | $10.63M | $9.60M | $12.20M | $14.04M | $7.76M | $3.64M | $64.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 17.9% | - | - | - | - | - | - | - |
| Net margin | 32.0% | - | - | - | - | - | - | - |
| Return on equity | 19.9% | -83.7% | -70.6% | -78.8% | -64.1% | -21.9% | - | - |
| Return on assets | 15.6% | -56.8% | -52.0% | -58.3% | -50.7% | -20.4% | -22.3% | -17.2% |
| Current ratio | 8.42 | 4.92 | 6.82 | 8.37 | 9.12 | 22.48 | 32.02 | 20.07 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $70.00M | $0 | $0 | $0 | $0 | - | - |
| Research and development | $7.39M | $7.00M | $6.30M | $7.44M | $9.32M | $10.51M | $12.30M | $12.91M | $12.56M | $13.54M | $15.29M | $16.15M |
| Selling, general and admin | $4.66M | $4.26M | $3.97M | $3.54M | $4.10M | $4.96M | $5.98M | $5.22M | $9.57M | $6.70M | $5.57M | $7.86M |
| Operating income | -$12.06M | -$11.26M | -$17.61M | -$10.98M | -$13.42M | $54.53M | -$18.27M | -$18.13M | -$22.13M | -$20.25M | -$20.86M | -$24.01M |
| Income tax | - | - | - | - | $0 | $226.0K | - | - | - | - | - | - |
| Net income | -$9.90M | -$9.04M | -$15.12M | -$8.50M | -$10.56M | $56.54M | -$15.98M | -$15.56M | -$19.91M | -$18.23M | -$19.41M | -$23.01M |
| EPS, basic | -$0.17 | -$0.16 | -$0.27 | -$0.15 | -$0.19 | $1.00 | -$0.28 | -$0.28 | -$0.36 | -$0.35 | - | -$0.45 |
| EPS, diluted | -$0.17 | -$0.16 | -$0.25 | -$0.15 | -$0.19 | $0.98 | -$0.28 | -$0.28 | -$0.36 | -$0.35 | - | -$0.45 |
| Diluted shares | 57.4M | 57.2M | - | 56.9M | 56.8M | 57.7M | - | 56.5M | 55.2M | 51.8M | - | 50.9M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $19.19M | $30.07M | $20.99M | $30.86M | $29.99M | $98.42M | $37.26M | $23.43M | $32.81M | $25.42M | $57.04M | $57.98M |
| Current assets | $115.39M | $122.97M | $132.44M | $138.99M | $146.73M | $155.68M | $101.18M | $115.54M | $126.75M | $118.81M | $134.03M | $147.05M |
| Total assets | $125.03M | $132.92M | $143.01M | $157.73M | $166.38M | $176.25M | $122.64M | $137.90M | $149.99M | $142.52M | $158.57M | $172.38M |
| Current liabilities | $15.84M | $14.53M | $15.73M | $15.54M | $16.80M | $16.85M | $20.57M | $20.80M | $18.44M | $16.85M | $19.65M | $15.07M |
| Total liabilities | $28.94M | $28.62M | $30.80M | $31.58M | $33.77M | $34.73M | $39.35M | $40.47M | $38.97M | $38.22M | $41.83M | $38.06M |
| Shareholders' equity | $96.09M | $104.30M | $112.21M | $126.15M | $132.61M | $141.52M | $83.28M | $97.43M | $110.52M | $104.31M | $116.74M | $134.32M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.97M | -$10.23M | -$6.79M | -$7.85M | -$9.16M | $53.41M | -$15.05M | -$11.32M | -$14.73M | -$21.20M | -$13.96M | -$18.36M |
| Capital expenditures | - | - | - | - | - | - | $0 | - | - | - | $0 | $33.0K |
| Free cash flow | - | - | - | - | - | - | -$15.05M | - | - | - | -$13.96M | -$18.39M |
| Investing cash flow | -$3.12M | $19.50M | -$2.89M | $8.59M | -$59.15M | $8.55M | $27.77M | $2.19M | $740.0K | -$13.73M | $12.25M | -$37.88M |
| Financing cash flow | $217.0K | -$185.0K | -$196.0K | $134.0K | -$116.0K | $32.0K | $291.0K | -$252.0K | $21.38M | $4.13M | -$46.0K | $71.93M |
| Stock-based compensation | $1.51M | $1.45M | $1.41M | $1.74M | $1.78M | $1.70M | $1.64M | $1.99M | $5.29M | $1.71M | $1.54M | $2.75M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -100.0% | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | 77.9% | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | 80.8% | - | - | - | - | - | - |
| Current ratio | 7.28 | 8.46 | 8.42 | 8.94 | 8.73 | 9.24 | 4.92 | 5.55 | 6.87 | 7.05 | 6.82 | 9.76 |
Source: XBRL data Black Diamond Therapeutics Inc. files with the SEC, latest filing dated Aug 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
BDTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BDTX | $0 | -100.0% | -$42.55M | - | $106.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
BDTX FAQ
6 questionsWhat is BDTX revenue?
Black Diamond Therapeutics Inc. (BDTX) reported $0 of revenue for the twelve months ended Jun 30, 2026. That is down 100.0% from the year before. Revenue for fiscal 2025 was $70.00M.Is BDTX profitable?
No. Black Diamond Therapeutics Inc. reported a net loss of $42.55M for the twelve months ended Jun 30, 2026.How much cash and debt does BDTX have?
Black Diamond Therapeutics Inc. reported $19.19M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is BDTX earnings per share?
Diluted earnings per share were -$0.73 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did BDTX last report financial results?
The latest statements here come from Black Diamond Therapeutics Inc.'s 10-Q filed on Aug 5, 2026, covering the period ended Jun 30, 2026.Where does this BDTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Black Diamond Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.